Kristina Jankovic, MD· @JankovicK · X·· 1 天前评分70
正文 · 机器翻译
#TALENT（#ESMO26 🇪🇸）：在 HR+/HER2-low 早期 #BreastCancer 中，新辅助 T-DXd 单药、T-DXd + anastrozole 或 T-DXd 序贯 TC 各组均显示出较高缓解率，但 pCR 均 <10%
需要更好的生物标志物来指导患者选择。
@OncoAlert
264 浏览 · 4 赞 · 4 转发 · 1 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org帖内回复
- Dr. Robert@robt_heartdoc
@JankovicK @OncoAlert The quiet finding in this figure: histology and IHC status didn't track with response at all. If nothing correlates, we're treating empirically and calling it precision oncology. My interest now is the EFS data.
来源：Kristina Jankovic, MD · x.com